In a deeply divided country, some people are dreading going home for the holidays. The anticipation of political conversation, about who voted for who, and about the racist, misogynist bigot who is planning to soon lead the United States.
So instead of talking through some of these issues (although I encourage civil discord!), the New York Times has given us a list of science and health stories from 2016 that you can discuss instead!
You could talk about how science views fat and what we know about weight loss! Or instead of talking about fleeing the country, perhaps consider a move to Mars instead! Or you can talk about dogs, and what science knows about their relationships!
Or you can talk about climate change, funding rates, the importance of teaching evolution and minorities in STEM! Not recommended by the NYTimes but always recommended by NiB.
Also, consider subscribing to the New York Times.
An 8 million dollar study came out in the Lancet ~5 years ago claiming that if you have Chronic Fatigue Syndrome, otherwise known as myalgic encephalomyelitis, the best treatment is exercise and psychotherapy.
However, after years of demanding they release their data (which they did under a court order), it has now been revealed that the study was just plain bad science.
Read about the controversy, the study, and the retraction (hopefully) over at STAT.
Sure, finding new and interesting species and describing them is exciting.
But finding new bacteria that cause a well understood disease? Equally if not more exciting (my little parasitic loving heart is all aflutter!).
While it has long been thought that lyme disease is caused by one bacterium (Borrelia burgdorferi), researchers at Mayo Clinic found something floating around in blood samples of people suspected of having Lyme disease that is totally different.
It has been named Borrelia mayonii, and it is remarkably similar to it’s lyme disease causing brethren. But it also has some important differences.
Read all about it over at NPR
Usually when an industry gets a booming industry it is largely due to profitability, which garners interest from investors.
But in biotech there is a section of the industry that is gaining investors and various firms chasing a similar goal. However, how that is happening is a mystery. The companies are burning through millions, hasn’t started clinical work on a drug candidate and it will be years, “if ever” before it has something commercializable.
What industry am I referring to? CRISPR-Cas9 technology. We’ve talked on the blog before about the possibilities CRISPR has to offer human health, but over at The Economist here’s a post about whether or not it can be all we dream it to be.
The Zika virus has been a rare tropical disease since it’s discovery in 1947. It’s a mosquito born virus that has been spreading at an alarming rate. It was previously confined to a few dozen cases ever (all in Africa) to millions of cases across South America.
The initial symptoms are quite mild. But there is evidence that it may in fact cause microcephaly, or babies born with small heads/brains. Which isn’t mild at all.
Consider Brazil. Over the past year ~ 1.5 million people have been infected. The virus is thought to have arrived with World Cup travelers in 2014, and spread rapidly. But what’s alarming, rather than simple flu like symptoms the rate of microcephaly in Brazil has increased 10 fold. (From several hundred to several thousand).
And what’s more, it has just been found in Puerto Rico, suggesting it could soon appear in the US.
Read about it over at Vox.
Jose Wesley, a Brazilian baby shown here on Dec. 23, 2015, was born with microcephaly. His mother was diagnosed with the Zika virus that researchers think may cause the birth defect. (AP Photo)
We have heard of viruses causing cancer (HPV) or even cancers that act like viruses (devil facial tumor virus).
But now there is a virus that can fight cancer! An engineered herpevirus provokes an immune response against cancer. And after a long hard road, it has been approved to treat certain types of cancer by the FDA!
Read about it over at Nature!
Killer T cells (orange) are recruited to attack malignant cells (mauve) in the viral-based cancer therapy T-VEC.